Genomics and the future of pharmacotherapy in psychiatry

References

• Allison DB, Kaprio J, Korkeila M, Koskenvuo M, Neale MC, Hayakawa K. The heritability of body mass index among an international sample of monozygotic twins reared apart. International Journal of Obesity Related Metabolic Disorders 1996; 20: 501–506
   PubMed Web of Science ®Google Scholar
• Angst J. Antidepressiver effect und genetische faktoren. Arzneimittelforschung 1964; 14( June suppl)496–500
   Google Scholar
• Arinami T, Gao M, Hamaguchi H, Toru M. A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia. Human Molecular Genetics, Apr 1997; 6(4)577–582
   PubMed Web of Science ®Google Scholar
• Basile VS, Masellis M, DeLuca V, Meltzer HY, Kennedy JL. 759C/T genetic variation of 5HT2C receptor and clozapine-induced weight gain. The Lancet 2002; 26: 128–129
   Google Scholar
• Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harrington H, et al. Influence of life stress on depression: Moderation by a polymorphism in the 5-HTT gene. Science 2003; 301(5631)386–389
   PubMed Web of Science ®Google Scholar
• Comuzzie AG, Blangero J, Mahaney MC, Mitchell BD, Hixson JE, Samollow PB, et al. Major gene with sex-specific effects influences fat mass in Mexican Americans. Genetic Epidemiology 1995; 12: 475–488
   PubMed Web of Science ®Google Scholar
• Comuzzie AG, Allison DB. The search for human obesity genes. Science 1998; 280: 1374–1377
   PubMed Web of Science ®Google Scholar
• Conley RR, Kelly DL. Management of treatment resistance in schizophrenia. Biological Psychiatry 2001; 50(11)898–911
   PubMed Web of Science ®Google Scholar
• Correll CU, Malhotra AK. Pharmacogenetics of antipsychotic-induced weight gain. Psychopharmacology 2004; 174: 477–489
   PubMed Web of Science ®Google Scholar
• de Leon J, Armstrong SC, Cozza KL. Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19. Psychosomatics 2006; 47(1)75–85
   PubMed Web of Science ®Google Scholar
• Ellingrod VL, Perry PJ, Ringold JC, Lund BJ, Bever-Stille K, Fleming F, et al. Weight gain associated with the -759 C/T polymorphism of the 5HT2C receptor and olanzapine. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics 2005; 134(1)76–78
   Web of Science ®Google Scholar
• Franchini L, Serretti A, Gasperini M, Smeraldi E. Familial concordance of fluvoxamine response as a tool for differentiating mood disorder pedigrees. Journal of Psychiatry Research 1998; 32: 255–259
   PubMed Web of Science ®Google Scholar
• Green MF, Kern RS, Braff DL, Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: Are we measuring the ‘right stuff’?. Schizophrenia Bulletin 2000; 26(1)119–136
   PubMed Web of Science ®Google Scholar
• Horáček J, Libiger J, Höschl C, Borzová K, Hendrychová I. Clozapine-induced concordant agranulocytosis in monozygotic twins. International Journal of Psychiatry in Clinical Practice 2001; 5: 71–73
   PubMed Web of Science ®Google Scholar
• Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Archives of General Psychiatry 1988; 45(9)789–796
   PubMed Web of Science ®Google Scholar
• Kane JM. Factors which can make patients difficult to treat. British Journal of Psychiatry Supplement 1996; 13: 10–14
   Google Scholar
• Klein RJ, Zeiss C, Chew EY, Tsai JY, Sackler RS, Haynes C, et al. Complement factor H polymorphism in age-related macular degeneration. Science 2005; 308(5720)385–389
   PubMed Web of Science ®Google Scholar
• Lane HY, Lee CC, Liu YC, Chang WH. Pharmacogenetic studies of response to risperidone and other newer atypical antipsychotics. Pharmacogenomics 2005; 6(2)139–149
   PubMed Web of Science ®Google Scholar
• Lee JH, Reed DR, Price RA. Familial risk ratios for extreme obesity: Implications for mapping human obesity genes. International Journal of Obesity Related Metabolic Disorders 1997; 21: 935–940
   PubMed Web of Science ®Google Scholar
• Lencz T, Robinson DG, Xu K, Ekholm J, Sevy S, Gundez-Bruce H, et al. DRD2 Promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients. American Journal of Psychiatry 2006; 163(3)529–531
   PubMed Web of Science ®Google Scholar
• Leucht S, Busch R, Hamman J, Kissling W, Kane JM. Rapid-onset hypothesis of antipsychotic drug action: A hypothesis tested, confirmed and extended. Biological Psychiatry 2005; 57(12)543–549
   PubMed Web of Science ®Google Scholar
• Levine JA, Eberhardt NL, Jensen MD. Role of nonexercise activity thermogenesis in resistance to fat gain in humans. Science 1999; 283(5399)212–214
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, , Clinical Antipsychotic Trials on Intervention Effectiveness (CATIE) Investigators, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England Journal of Medicine 2005; 353(12)1209–1223
   PubMed Web of Science ®Google Scholar
• Malhotra AK, Murphy Jr G. M, Kennedy JL. Pharmacogenetics of psychotropic drug response. American Journal of Psychiatry 2004; 161(5)780–796
   PubMed Web of Science ®Google Scholar
• Malhotra AK, Athanasiou M, Reed CR, Dain B, Carr J, Whalen H, et al. Discovery of genetic markers associated with clozapine induced agranulocytosis. American Journal of Medical Genetics, Part B Neuropsychiatric Genetics 2005; 138b(1)22
   Web of Science ®Google Scholar
• Mata I, Madoz V, Arranz MJ, Sham P, Murray RM. Olanzapine: Concordant response in monozygotic twins with schizophrenia. British Journal of Psychiatry 2001; 178(1)86
   PubMed Web of Science ®Google Scholar
• Mata I, Crespo-Facorro B, Perez-Iglesias R, Carrasco-Marin E, Arranz MJ, Pelayo-Teran JM, et al. Association between the interleukin-1 receptor antagonist gene and negative symptom improvement during antipsychotic treatmentdagger. American Journal Medical Genetics Bulletin of Neuropsychiatric Genetics 2006, in press
   PubMed Web of Science ®Google Scholar
• McMahon FJ, Buervenich S, Charney D, Lipsky R, Rush AJ, Wilson AF, et al. Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. American Journal of Human Genetics 2006; 78(5)804–814
   PubMed Web of Science ®Google Scholar
• Miller DD, Ellingrod VL, Holman TL, Buckley PF, Arndt S. Clozapine-induced weight gain associated with the 5HT2C receptor-759C/T polymorphism. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics 2005; 133(1)97–100
   Web of Science ®Google Scholar
• Montgomery SA. The failure of placebo-controlled studies. ECNP Consensus Meeting, September 13, 1997, Vienna. European College of Neuropsychopharmacology. European Neuropsychopharmacology 1999; 9(3)271–276
   PubMed Web of Science ®Google Scholar
• Murphy Jr G. M, Kremer C, Rodrigues HE, Schatzberg AF. Pharmacogenetics of antidepressant medication intolerance. American Journal of Psychiatry 2003; 160(10)1830–1835
   PubMed Web of Science ®Google Scholar
• Pare C. M.B., Rees L, Sainsbury MJ. Differentiation of two genetically specific types of depression by the response to anti-depressants. The Lancet 1962; 2: 1340–1343
   PubMed Web of Science ®Google Scholar
• Pollock BG, Ferrell RE, Mulsant BH, Mazumdar S, Miller M, Sweet RA, et al. Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology 2000; 23: 587–590
   PubMed Web of Science ®Google Scholar
• Ratzoni G, Gothelf D, Brand-Gothelf A, Reidman J, Kikinzon L, Gal G, et al. Weight gain associated with olanzapine and risperidone in adolescent patients: A comparative prospective study. Journal of the American Academy of Child and Adolescent Psychiatry 2002; 41(3)337–343
   PubMed Web of Science ®Google Scholar
• Reynolds GP, Zhang ZJ, Zhang XB. Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism. The Lancet 2002; 359: 2086–2087
   PubMed Web of Science ®Google Scholar
• Reynolds GP, Zhang ZJ, Zhang XB. Polymorphism of the promoter region of the serotonin 5-HT(2C) receptor gene and clozapine-induced weight gain. American Journal of Psychiatry 2003; 160: 677–679
   PubMed Web of Science ®Google Scholar
• Reynolds GP, Yao ZJ, Zhang XB, Sun J, Zhang ZJ. Pharmacogenetics of treatment in first-episode schizophrenia: D3 and 5-HT2C receptor polymorphisms separately associate with positive and negative symptom response. European Neuropsychopharmacology 2005; 15(2)143–151
   PubMed Web of Science ®Google Scholar
• Reynolds GP, Arranz B, Templeman LA, Fertuzinhos S, San L. Effect of 5-HT1A receptor gene polymorphism on negative and depressive symptom response to antipsychotic treatment of drug-naïve psychotic patients. American Journal of Psychiatry 2006; 163(10)1826–1829
   PubMed Web of Science ®Google Scholar
• Robinson DG, Woerner M, Alvir J, Ma J, Bilder R, Goldman R, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Archives of General Psychiatry 1999; 56: 241–247
   PubMed Web of Science ®Google Scholar
• Robinson DG, Woerner MG, McMeniman M, Mendelowitz A, Bilder RM. Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder. American Journal of Psychiatry 2004; 161: 473–479
   PubMed Web of Science ®Google Scholar
• Safer DJ. A comparison of risperidone-induced weight gain across the age span. Journal of Clinical Psychopharmacology 2004; 24: 429–436
   PubMed Web of Science ®Google Scholar
• Sikich L, Hamer RM, Bashford RA, Sheitman BB, Lieberman JA. A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth; A double-blind, randomized, 8-week trial. Neuropsychopharmacology 2004; 29(1)133–145
   PubMed Web of Science ®Google Scholar
• Smeraldi E, Zanardi R, Benedetti F, DiBella D, Perez J, Catalano M. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Molecular Psychiatry 1998; 3: 508–511
   PubMed Web of Science ®Google Scholar
• Tecott LH, Sun LM, Akana SF, Strack AM, Lowenstein DH, Dallman MF, et al. Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors. Nature 1995; 374: 542–546
   PubMed Web of Science ®Google Scholar
• Templeman LA, Reynolds GP, Arranz B, San L. Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis. Pharmacogenetics and Genomics 2005; 15(4)195–200
   PubMedGoogle Scholar
• The International HapMap Consortium. A haplotype map of the human genome. Nature 2005; 437: 1299–1320
   PubMed Web of Science ®Google Scholar
• Theisen FM, Hinney A, Bromel T, Heinzel-Gutenbrunner M, Martin M, Kreig JC, et al. Lack of association between the −759C/T polymorphism of the 5-HT2c receptor gene and clozapine-induced weight gain among German schizophrenic individuals. Psychiatric Genetics 2004; 14(3)139–142
   PubMed Web of Science ®Google Scholar
• Theisen FM, Gebhardt S, Haberhausen M, Heinzel-Gutenbrunner M, Wehmeier PM, Krieg J, et al. Clozapine-induced weight gain: A study in monozygotic twins and same-sex sib pairs. Psychiatric Genetics 2005; 15: 285–289
   PubMed Web of Science ®Google Scholar
• Tsai SJ, Hong CJ, Yu YW, Lin CH. −759C/T genetic variation of 5HT(2C) receptor and clozapine-induced weight gain. The Lancet 2002; 360: 1790
   PubMed Web of Science ®Google Scholar
• Vojvoda D, Grimmell K, Sernyak M, Mazure CM. Monozygotic twins concordant for response to clozapine. The Lancet 1996; 347: 61
   PubMed Web of Science ®Google Scholar
• Wehmeier PM, Gebhardt S, Schmidtke J, Remschmidt H, Hebebrand J, Theisen FM. Clozapine: Weight gain in a pair of monozygotic twins concordant for schizophrenia and mild mental retardation. Psychiatry Research 2005; 133: 273–276
   PubMed Web of Science ®Google Scholar
• Wetterling T, Mussigbrodt HE. Weight gain: Side effect of atypical neuroleptics?. Journal of Clinical Psychopharmacology 1999; 19(4)316–321
   PubMed Web of Science ®Google Scholar
• Woods SW, Martin A, Spector SG, McGlashan TH. Effects of development on olanzapine-associated adverse events. Journal of the American Academy of Child and Adolescent Psychiatry 2002; 41(12)1439–1446
   PubMed Web of Science ®Google Scholar
• Zanardi R, Benedetti F, DiBella D, Catalano M, Smeraldi E. Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of the serotonin transporter gene. Journal of Clinical Psychopharmacology 2000; 20: 105–107
   PubMed Web of Science ®Google Scholar